.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,090,619

« Back to Dashboard

Details for Patent: 9,090,619

Title:Modulators of ATP-binding cassette transporters
Abstract: The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Inventor(s): Hadida-Ruah; Sara (La Jolla, CA), Hazlewood; Anna (San Diego, CA), Grootenhuis; Peter (San Diego, CA), Van Goor; Fredrick (San Diego, CA), Singh; Ashvani (San Diego, CA), Zhou; Jinglan (San Diego, CA), McCartney; Jason (Cardiff by the Sea, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Filing Date:Jul 30, 2014
Application Number:14/446,870
Claims:1. A compound having formula A-I: ##STR00242## or a salt thereof; wherein: G.sub.1 is hydrogen, R', C(O)R', C(S)R', S(O)R', S(O).sub.2R', Si(CH.sub.3).sub.2R', P(O)(OR').sub.3, P(S)(OR').sub.3, or B(OR').sub.2; G.sub.2 is halo, CN, CF.sub.3, isopropyl, or phenyl wherein said isopropyl or phenyl is optionally substituted with up to 3 substituents independently selected from WR.sup.W; G.sub.3 is an isopropyl or a C3-C10 cycloaliphatic ring, wherein said G.sub.3 is optionally substituted with up to 3 substituents independently selected from WR.sup.W; provided that when G.sub.1 is methyl, G.sub.3 is tert-butyl, then G.sub.2 is not 2-amino-4-methoxy-5-tert-butyl-phenyl; W is a bond or is an optionally substituted C.sub.1-C.sub.6 alkylidene chain, wherein up to two methylene units of W are optionally and independently replaced by --CO--, --CS--, --COCO--, --CONR'--, --CONR'NR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--, --NR'CONR'--, --OCONR'--, --NR'NR', --NR'NR'CO--, --NR'CO--, --S--, --SO, --SO.sub.2--, --NR'--, --SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--; R.sup.W is independently R', halo, NO.sub.2, CN, CF.sub.3, or OCF.sub.3; and R' is independently selected from hydrogen or an optionally substituted group selected from a C.sub.1-C.sub.8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R' are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

2. The compound according to claim 1, wherein: G.sub.1 is hydrogen; G.sub.2 is halo or isopropyl, wherein said isopropyl is optionally substituted with up to 3 substituents independently selected from R'; and G.sub.3 is an isopropyl or a C3-C10 cycloaliphatic ring, wherein said G.sub.3 is optionally substituted with up to 3 substituents independently selected from R'.

3. The compound according to claim 2, wherein: G.sub.1 is hydrogen; G.sub.2 is halo; and G.sub.3 is a C3-C10 cycloaliphatic ring, wherein said G.sub.3 is optionally substituted with up to 3 substituents independently selected from methyl, ethyl, propyl, or butyl.

4. The compound according to claim 1, wherein: G.sub.1 is hydrogen; G.sub.2 is CN, halo, or CF.sub.3; and G.sub.3 is an isopropyl or a C3-C10 cycloaliphatic ring, wherein said G.sub.3 is optionally substituted with up to 3 substituents independently selected from R'.

5. The compound according to claim 1, wherein: G.sub.1 is hydrogen; G.sub.2 is phenyl, wherein said phenyl is optionally substituted with up to 3 substituents independently selected from --OC1-C4 alkyl, CF.sub.3, halo, or CN; and G.sub.3 is an isopropyl or a C3-C10 cycloaliphatic ring, wherein said G.sub.3 is optionally substituted with up to 3 substituents independently selected from R'.

6. The compound according to claim 1, wherein G.sub.3 is selected from optionally substituted cyclopentyl, cyclohexyl, cycloheptyl, or adamantyl.

7. The compound according to claim 1, wherein G.sub.3 is C3-C8 branched aliphatic chain.

8. The compound according to claim 1, wherein the compound is C-9 ##STR00243##

9. A process for the preparation of a compound having the formula FF ##STR00244## comprising hydrogenating a compound having the formula EE ##STR00245## in the presence of a Palladium catalyst wherein G.sub.2 is halo, CN, CF.sub.3, isopropyl, or phenyl wherein said isopropyl or phenyl is optionally substituted with up to 3 substituents independently selected from WR.sup.W; G.sub.3 is an isopropyl or a C.sub.3-C.sub.10 cycloaliphatic ring, wherein said G.sub.3 is optionally substituted with up to 3 substituents independently selected from WR.sup.W; W is a bond or is a C.sub.1-C.sub.6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by --CO--, --CS--, --COCO--, --CONR'--, --CONR'NR'--, --CO.sub.2--, --OCO--, --NR'CO.sub.2--, --O--, --NR'CONR'--, --OCONR'--, --NR'NR', --NR'NR'CO--, --NR'CO--, --S--, --SO, --SO.sub.2--, --NR'--, --SO.sub.2NR'--, NR'SO.sub.2--, or --NR'SO.sub.2NR'--; R.sup.W is independently R', halo, NO.sub.2, CN, CF.sub.3, or OCF.sub.3; and R' is independently selected from hydrogen or a group selected from a C.sub.1-C.sub.8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R' are taken together with the atom(s) to which they are bound to form a 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

10. A process for preparing the compound C-9 ##STR00246## comprising the steps of: contacting 2,4-di-tert-butylphenol with methyl chloroformate to produce 2,4-di-tert-butylphenyl methyl carbonate ##STR00247## 2,4-di-tert-butylphenyl methyl carbonate contacting 2,4-di-tert-butylphenyl methyl carbonate with a mixture of nitric acid and sulfuric acid to produce 2,4-di-tert-butyl-5-nitrophenyl methyl carbonate ##STR00248## 2,4-di-tert-butyl-5-nitrophenyl methyl carbonate contacting 2,4-di-tert-butyl-5-nitrophenyl methyl carbonate with a mixture of methanol and KOH to produce 2,4-di-tert-butyl-5-nitrophenol ##STR00249## and 2,4-di-tert-butyl-5-nitrophenol hydrogenating 2,4-di-tert-butyl-5-nitrophenol in the presence of a palladium catalyst.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc